FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.041,38 -1.182,27 (-1,96%)
Novozymes A/S (0Q4U.IL)
| Chiusura precedente | 383,35 |
| Aperto | 387,20 |
| Denaro | 291,00 x 0 |
| Lettera | 398,80 x 0 |
| Min-Max giorno | 384,80 - 391,50 |
| Intervallo di 52 settimane | 274,90 - 421,40 |
| Volume | |
| Media Volume | 550.852 |
| Capitalizzazione | 108,198B |
| Beta (5 anni mensile) | 0,44 |
| Rapporto PE (ttm) | 31,73 |
| EPS (ttm) | 12,32 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | 10,20 (3,59%) |
| Data ex dividendo | 11 ott 2023 |
| Stima target 1A | 411,63 |
GlobeNewswireNovozymes launches new biosolution to redefine the plant-based meat experience by enhancing texture and encouraging more consumers to choose plant-based alternatives
Novozymes is excited to offer Vertera® ProBite as a game-changing solution to the plant-based meat industry, opening up new possibilities to create today's and tomorrow's plant-based meat products with advanced texture and consumer-friendly labels. The new product is a part of Novozymes’ commitment to driving innovation in biosolutions and promoting sustainable food choices. Copenhagen – September 28: Today marks an important milestone in the evolution of plant-based meat innovation with the lau
- GlobeNewswire
Novozymes and Bactolife join forces to significantly reduce post weaning diarrhea and antibiotic use among weaner pigs
The two companies have signed a joint development and commercialization agreement to launch feed additive Ablacto+. The game changing biosolution uses binding proteins to stabilize the gut of piglets, thereby reducing the need for antibiotic consumption. Copenhagen, Denmark – 4 September 2023. Novozymes and the Danish industrial biotech company, Bactolife, have signed a joint development and commercialization agreement to finish development and launch the biosolution Ablacto+. The promising prod
- GlobeNewswire
Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook
After the first half of 2023, Novozymes sees overall stability in a volatile environment and delivers 3% organic sales growth. Following destocking and lower consumer demand, the organic full-year sales growth outlook is slightly narrowed from 4-7% to 4-6%. Growth is expected to be driven mainly by pricing. COPENHAGEN, Denmark – August 9, 2023. Novozymes delivers 3% organic sales growth, an EBIT-margin of 25% before special items, and ROIC including goodwill of 17% before special items in the fi
